Head to Head Comparison: Achieve Life Sciences (ACHV) and BG Medicine (BGMD)

Achieve Life Sciences (NASDAQ: ACHV) and BG Medicine (OTCMKTS:BGMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Valuation & Earnings

How to Become a New Pot Stock Millionaire

This table compares Achieve Life Sciences and BG Medicine’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achieve Life Sciences $5.06 million 3.20 -$10.58 million N/A N/A
BG Medicine $1.57 million 0.26 -$5.30 million N/A N/A

BG Medicine has lower revenue, but higher earnings than Achieve Life Sciences.

Institutional & Insider Ownership

3.5% of Achieve Life Sciences shares are owned by institutional investors. 35.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 6.5% of BG Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Achieve Life Sciences and BG Medicine, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Achieve Life Sciences 0 0 0 0 N/A
BG Medicine 0 0 0 0 N/A

Risk and Volatility

Achieve Life Sciences has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, BG Medicine has a beta of 3.32, suggesting that its stock price is 232% more volatile than the S&P 500.


This table compares Achieve Life Sciences and BG Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Achieve Life Sciences N/A -138.65% -118.38%
BG Medicine N/A N/A N/A

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.

BG Medicine Company Profile

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply